VANCOUVER, BC, and CONSHOHOCKEN, PA, April 12 /PRNewswire/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, announced today that it has been named to FierceBiotech’s annual Fierce 15 list of top biotech companies to watch. This distinction, which was announced during the annual BIO meeting in Chicago, recognizes Neuromed as one of the top emerging biotech companies in 2006.
FierceBiotech, an internationally recognized email newsletter covering the biotechnology and pharmaceutical markets, evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.
“We are very pleased to be selected as a member of the Fierce 15 which recognizes the rapid progress Neuromed has made to establish itself as a leading developer of calcium channel blockers to treat chronic pain and other neurological disorders,” said Dr. Christopher Gallen, President and CEO, Neuromed. “Our momentum continues to build following our recent financing and the recent research and licensing deal with Merck & Co., Inc. to develop and commercialize our lead compound, NMED-160, as well as other compounds that selectively target the N-type calcium channel.”
The Fierce 15 celebrates the spirit of being “fierce” - championing innovation and creativity, even in the face of intense competition. The list of Fierce 15 companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
About Neuromed
Neuromed is a privately held biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular disease such as hypertension. Located in Vancouver, Canada and Conshohocken, USA, the Company’s drug development programs are designed around validated clinical targets associated with large unmet markets. Neuromed exclusively focuses on calcium channels as drug targets and is the first company to take an orally available drug selectively targeting neuronal calcium channels into human clinical trials. For more information visit www.neuromed.com.
About FierceBiotech
FierceBiotech, an internationally recognized email newsletter for the biotech industry, provides more than 42,000 executives a must-read briefing on the day’s top stories in the biotech and pharmaceutical industries. Visit www.fiercebiotech.com for additional information.
For more information regarding this press release, contact: Communications contact in Canada Catherine Ducharme Neuromed Pharmaceuticals Cell : (604) 813-6104 Phone: (604) 909-2547 Email: cducharme@neuromed.com Communications contact in the US Matt Dallas Financial Dynamics Business Communications Phone: (212) 850-5627 Cell: (917) 363-1333 Email: mdallas@fd-us.com
Neuromed Pharmaceuticals Ltd.
CONTACT: Communications contact in Canada: Catherine Ducharme, NeuromedPharmaceuticals, Cell : (604) 813-6104, Phone: (604) 909-2547, Email:cducharme@neuromed.com; Communications contact in the US: Matt Dallas,Financial Dynamics, Business Communications, Phone: (212) 850-5627, Cell:(917) 363-1333, Email: mdallas@fd-us.com